Get the Stockscreener App
18.87
3.97%
-0.78
After Hours:
18.87
Viridian Therapeutics Inc stock is traded at $18.87, with a volume of 448.15K.
It is down -3.97% in the last 24 hours and up +5.01% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$19.65
Open:
$19.56
24h Volume:
448.15K
Relative Volume:
0.58
Market Cap:
$1.54B
Revenue:
$305.00K
Net Income/Loss:
$-328.98M
P/E Ratio:
-4.9269
EPS:
-3.83
Net Cash Flow:
$-309.60M
1W Performance:
+0.80%
1M Performance:
+5.01%
6M Performance:
+13.33%
1Y Performance:
-8.84%
1-Day Range:
$18.86
$19.57
1-Week Range:
$18.63
$20.51
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.87 | 1.62B | 305.00K | -328.98M | -309.60M | -3.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics, Inc. $VRDN Shares Sold by Alliancebernstein L.P. - MarketBeat
Adage Capital Partners GP L.L.C. Sells 555,414 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Invesco Ltd. Acquires 14,672 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Octagon Capital Advisors LP Reduces Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Exome Asset Management LLC Purchases Shares of 217,294 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. $VRDN is Yiheng Capital Management L.P.'s 10th Largest Position - MarketBeat
Viridian Therapeutics Inc. Approaches Support With Recovery in SightMarket Risk Analysis & Accurate Trade Setup Notifications - beatles.ru
Can Viridian Therapeutics Inc. lead its sector in growthMarket Weekly Review & Low Drawdown Investment Strategies - 뉴스영
ADAR1 Capital Management LLC Acquires 53,000 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Key External Factors That Drive Viridian Therapeutics Inc. Stock Price MovementsJobs Report & Smart Swing Trading Alerts - Newser
Will breakout in Viridian Therapeutics Inc. lead to full recoveryEarnings Recap Summary & Consistent Return Investment Signals - Newser
Is a relief rally coming for Viridian Therapeutics Inc. holdersEarnings Miss & High Return Trade Opportunity Guides - Newser
Will Viridian Therapeutics Inc. stock go up in YEARBull Run & Smart Swing Trading Alerts - خودرو بانک
Rafferty Asset Management LLC Reduces Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Pattern recognition hints at Viridian Therapeutics Inc. upsideSwing Trade & Real-Time Volume Triggers - Newser
Paradigm Biocapital Advisors LP Boosts Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Will Viridian Therapeutics Inc. outperform during market ralliesQuarterly Earnings Summary & Verified Momentum Watchlists - خودرو بانک
Will Viridian Therapeutics Inc. rebound enough to break evenPortfolio Gains Report & Step-by-Step Trade Execution Guides - Newser
Technical analysis overview for Viridian Therapeutics Inc. stock2025 Year in Review & Smart Allocation Stock Reports - Newser
How to use Fibonacci retracement on Viridian Therapeutics Inc.Weekly Market Report & AI Enhanced Trade Execution Alerts - Newser
How to forecast Viridian Therapeutics Inc. trends using time seriesQuarterly Profit Report & Risk Managed Investment Strategies - Newser
Can you recover from losses in Viridian Therapeutics Inc.2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - Newser
Will Viridian Therapeutics Inc. bounce back from current supportJuly 2025 Selloffs & Safe Capital Growth Tips - Newser
Candlestick signals on Viridian Therapeutics Inc. stock todayProduct Launch & Verified High Yield Trade Plans - Newser
Combining price and volume data for Viridian Therapeutics Inc.July 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Viridian Therapeutics shares fall 1.85% premarket after announcing inducement grants to new employees. - AInvest
Has Viridian Therapeutics Inc. found a price floorJuly 2025 Action & Risk Controlled Swing Trade Alerts - Newser
Viridian Therapeutics, Inc. $VRDN Shares Bought by Wellington Management Group LLP - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 - BioSpace
Viridian Therapeutics Inc. stock momentum explained2025 Macro Impact & Capital Protection Trading Alerts - Newser
Strategic Alignment of Executive Compensation and Shareholder Value: Analyzing Viridian Therapeutics' Inducement Grants Under Nasdaq Rule 5635(c)(4) - AInvest
Can Viridian Therapeutics Inc. expand its profit margins2025 Momentum Check & Daily Volume Surge Signals - خودرو بانک
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Can Viridian Therapeutics Inc. reach all time highs this yearWeekly Trading Summary & High Accuracy Swing Entry Alerts - خودرو بانک
Measuring Viridian Therapeutics Inc.’s beta against major indicesM&A Rumor & Daily Stock Trend Reports - Newser
Published on: 2025-09-03 09:36:11 - Newser
Stock Recap: Can Viridian Therapeutics Inc. lead its sector in growthWeekly Trade Report & Consistent Profit Trading Strategies - خودرو بانک
Should you buy the dip on Viridian Therapeutics Inc.Quarterly Risk Review & Low Risk Profit Maximizing Plans - خودرو بانک
Is Viridian Therapeutics Inc. trading at a discountJuly 2025 Weekly Recap & Daily Entry Point Alerts - خودرو بانک
Leading vs lagging indicators on Viridian Therapeutics Inc. performanceQuarterly Investment Review & Weekly High Potential Alerts - Newser
Does Viridian Therapeutics Inc. have a competitive edgeJuly 2025 Weekly Recap & Community Consensus Trade Alerts - خودرو بانک
Will Viridian Therapeutics Inc. see short term momentum2025 Buyback Activity & Long Hold Capital Preservation Tips - Newser
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):